HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

FDA closes 2024 with string of early alerts on device safety risks

Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. In the final days of 2024, the

January 3, 2025

Gilead and Arcus Biosciences expand oncology partnership deal

Share this article The investment from Gilead in Arcus is aimed at expediting the growth of co-development programmes for cancer indications. Credit: Kateryna Kon /

January 30, 2024

American Heart Association funds research to assess racial bias in cardiovascular treatment algorithms

As part of a focused effort to assess current cardiovascular treatment algorithms for racial bias, the American Heart Association, the single largest non-government supporter of

August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.